2025 ASCO GI | 彰显中国科研实力，结直肠癌领域前沿研究奏响时代强音

前言

2025年美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO GI）将于1月23日至25日在美国加利福尼亚州旧金山举行，旨在为世界肿瘤学者传递国际消化肿瘤领域的最新研究进展。目前大会官网已披露了摘要标题，大会第三日聚焦结直肠癌领域，多项中国研究入选，医脉通特此整理相关摘要标题，让我们先睹为快。

Poster session

01

摘要号：56

Survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis.

讲者：Hsiang-Lin Tsai 高雄医学大学

02

摘要号：57

Effectiveness of anti-epidermal growth factor receptor agents in elderly patients (age ≥ 70 years) with RAS wild-type metastatic colorectal cancer: Nationwide real-world data.

讲者：Chao-Yuan Wang 高雄医学大学附设中和纪念医院

03

摘要号：68

Vascular endothelial growth factor receptor (VEGFR) -tyrosine kinase inhibitors combined with programmed death receptor-1 (PD-1) inhibitors as third- or later-line treatment in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): A retrospective study.

讲者：Xiaoqian Li 山东省肿瘤医院

04

摘要号：77

Bevacizumab plus mFOLFOX6/FOLFIRI sequential bevacizumab plus capecitabine maintenance in RAS-mutated advanced colorectal cancer: A real-world study of first-line/second-line conversion therapy.

讲者：Ying Yan 中国科学技术大学附属第一医院

05

摘要号：133

Total neoadjuvant therapy with FOLFOX plus bevacizumab and short-course radiotherapy for Ras mutant, high-risk, locally advanced rectal cancer: The TRAINER trial.

讲者：Jingyi Liu 上海交通大学医学院附属瑞金医院

06

摘要号：145

Updated analysis of a phase 2 study of fruquintinib plus trifluridine/tipiracil (TAS-102) as third-line treatment in patients with metastatic colorectal adenocarcinoma.

讲者：彭建军 中山大学附属第一医院

07

摘要号：150

Short-course radiotherapy-based total neoadjuvant therapy combined with tislelizumab in the treatment of locally advanced rectal cancer (Neo-STAR): Early outcomes of a prospective, randomized phase II trial.

讲者：吴凤鹏 河北医科大学第四医院

08

摘要号：151

Fruquintinib combined with FOLFIRI/mFOLFOX6 as second-line treatment in patients with RAS-mutant metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.

讲者：Yun Xu 复旦大学附属肿瘤医院

09

摘要号：155

Phase II study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second‐line therapy for patients with metastatic colorectal cancer.

讲者：Wenwei Yang 中国医学科学院肿瘤医院

10

摘要号：157

Prognosis of patients with liver single-organ metastases: Updated survival results of BBCAPX-II.

讲者：袁瑛 浙江大学医学院附属第二医院

11

摘要号：166

Efficacy and safety of fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.

讲者：廖旺军 南方医科大学南方医院

12

摘要号：167

Updated survival results of ZL-IRIAN: Irinotecan plus anlotinib or in combination with penpulimab as second-line treatment of metastatic colorectal cancer.

讲者：王辰辰 复旦大学附属肿瘤医院

13

摘要号：170

Updated efficacy and subgroup analysis of first-line serplulimab plus bevacizumab and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.

讲者：徐瑞华 中山大学肿瘤防治中心

14

摘要号：174

Exploratory study of TAS-102 combined with intermittent administration of fruquintinib in the treatment of third-line metastatic colorectal cancer.

讲者：Jiayu Niu 中国科学技术大学附属第一医院

15

摘要号：177

OP-TNT: Phase II study of total neoadjuvant chemoradiotherapy followed by local resection for early distal rectal carcinoma.

讲者：Zhang Xian 复旦大学附属中山医院

16

摘要号：185

Neoadjuvant PD-1 blockade in mismatch repair-deficient or microsatellite instability-high, locally advanced and resectable colorectal cancer: A retrospective real-world analysis.

讲者：Yugui Lian 郑州大学第一附属医院

17

摘要号：190

QL1203 vs placebo plus mFOLFOX6 as first-line therapy in RAS wild-type, metastatic colorectal cancer (mCRC): Interim analysis (IA) of a multicenter, randomized, double-blinded, parallel, phase 3 trial.

讲者：郭伟剑 复旦大学附属肿瘤医院

18

摘要号：192

Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, phase II study (UNION TNT).

讲者：林振宇 华中科技大学同济医学院附属协和医院

19

摘要号：194

Efficacy and safety of anlotinib as a later-line treatment for advanced colorectal cancer.

讲者：宋扬 空军军医大学唐都医院

20

摘要号：195

Liposomal irinotecan + 5-fluorouracil + leucovorin + bevacizumab as second-line therapy in metastatic colorectal cancer (IRIS): A multi-center, single-arm, prospective, phase II study.

讲者：胡旭华 河北医科大学第四医院

21

摘要号：198

Preliminary safety and efficacy of upfront FOLFOXIRI and bevacizumab with cadonilimab in patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer: A multicenter phase II study (SYLT-026).

讲者：林榕波 福建省肿瘤医院

22

摘要号：201

Neoadjuvant chemotherapy with FOLFOXIRI for high-risk relapsed locally advanced colon cancer: A single-arm phase II trial.

讲者：Yuwen Zhou 四川大学华西医院

23

摘要号：203

Real-world outcomes of targeted therapies and local interventions in BRAF V600E–mutated metastatic colorectal cancer: A single-center retrospective study.

讲者：Ziqin Lin 中山大学附属第六医院

24

摘要号：LBA210

Short-course radiation(SCRT) followed by 6 cycles of cadonilimab plus mFOLFOX6 as neoadjuvant therapy for patients with locally advanced rectal cancer (LARC): A multicenter, single arm, phase II trial (NeoCaCRT).

讲者：何婉 深圳市人民医院

25

摘要号：240

Utilization of SDC2 gene in conjunction with SEPTIN9 gene methylation analysis for the diagnosis and efficacy assessment of colorectal cancer.

讲者：Rongjia Xie 同济大学附属第十人民医院

26

摘要号：246

Effects of targeting CTMP on immunogenicity of MSI-L colon adenocarcinoma cells by metabolism and cell cycle modulation.

讲者：Cheng Gu 同济大学附属第十人民医院

27

摘要号：278

Comprehensive landscape of FGFR variations and prognosis revelance in colorectal cancer from circulating tumor DNA and tissue gene analyses in 2083 patients.

讲者：Xiaoshuang Lyu 中山大学附属第六医院

28

摘要号：292

The role and molecular mechanism of GDF5 in regulating cell migration and angiogenesis via the Hippo-YAP signaling pathway in colorectal cancer.

讲者：Peijie Lei 青岛大学附属医院

29

摘要号：298

Development and validation of a deep learning–based pathomics signature for prognosis and chemotherapy benefits in colorectal cancer: A retrospective multicenter cohort study.

讲者：Shenghan Lou 哈尔滨医科大学附属肿瘤医院

Trials in Progress Poster Session

01

摘要号：TPS314

A phase II, randomized study of JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC).

讲者：许剑民 复旦大学附属中山医院

02

摘要号：TPS315

Chemoradiotherapy (CRT) followed by sequential tislelizumab (TIS) + CAPOX and TIS monotherapy for organ preservation in locally advanced low rectal cancer.

讲者：Wentao Tang 复旦大学附属中山医院

03

摘要号：TPS316

Cetuximab and vemurafenib plus liposomal irinotecan (II), leucovorin and fluorouracil for BRAFV600E-mutated advanced colorectal cancer (IMPROVEMENT2): A multicenter, open-label, randomized controlled trial.

讲者：王湛 海军军医大学第二附属医院

备注：排名不分先后，按照摘要号进行排序

如有遗漏或任何问题，请给我们留言~

撰写：Babel

排版：Aurora

执行：Aurora

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。